Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Investigational New Drugs

Volumn 28, Issue 3, 2010, Pages 334-342

  Buckner, Jan C ^a   Forouzesh, Bahram ^b,c,d,f   Erlichman, Charles ^a   Hidalgo, Manuel ^b,c,g   Boni, Joseph P ^e   Dukart, Gary ^e   Berkenblit, Anna ^e   Rowinsky, Eric K ^b,c,h  

^a MAYO CLINIC   (United States)

^b CTRC Institute for Drug Development   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

^f LIVERPOOL HOSPITAL   (Australia)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h ImClone Systems   (United States)

Author keywords

MTOR; Pharmacokinetics; Phase I; Targeted chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DIPHENHYDRAMINE; FIBRINOGEN; PREDNISONE; RAPAMYCIN; TEMSIROLIMUS;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLADDER CANCER; BREAST CANCER; CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; LEIOMYOSARCOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; METASTASIS POTENTIAL; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROBLASTOMA; OSTEOSARCOMA; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URTICARIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; TREATMENT OUTCOME;

EID: 77952236657     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9257-1     Document Type: Article

References (34)

1. T Schmelzle MN Hall 2000 TOR, a central controller of cell growth Cell 103 253 262 10.1016/S0092-8674(00) 00117-3 10.1016/S0092-8674(00)00117-3 1:CAS:528:DC%2BD3cXns1CltrY%3D 11057898
2. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 10.1038/nrc1362 10.1038/nrc1362 1:CAS:528: DC%2BD2cXjsFSlu7Y%3D 15122205
3. D Del Bufalo L Ciuffreda D Trisciuoglio, et al. 2006 Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus Cancer Res 66 5549 5554 10.1158/0008-5472.CAN-05-2825 10.1158/0008-5472.CAN-05-2825 16740688 (Pubitemid 43927103)
4. AJ Pantuck G Zeng AS Belldegrun RA Figlin 2003 Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway Clin Cancer Res 9 4641 4652 1:CAS:528:DC%2BD3sXosVCqu7c%3D 14581333
5. JS Skotnicki CL Leone AL Smith 2001 Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 Clin Cancer Res 7 3749S 3750S
6. K Yu L Toral-Barza C Discafani, et al. 2001 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 249 258 10.1677/erc.0.0080249 10.1677/erc.0.0080249 11566616 (Pubitemid 32947647)
7. L Dudkin MB Dilling PJ Cheshire, et al. 2001 Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 1758 1764 1:CAS:528:DC%2BD3MXltV2hsL4%3D 11410517
8. GV Thomas C Tran IK Mellinghoff, et al. 2006 Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 122 127 10.1038/nm1337 10.1038/nm1337 1:CAS:528:DC%2BD28Xht1Knuw%3D%3D 16341243 (Pubitemid 43050086)
9. P Frost F Moatamed B Hoang, et al. 2004 In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model Blood 104 4181 4187 10.1182/blood-2004-03-1153 10.1182/blood-2004-03-1153 1:CAS:528:DC%2BD2cXhtFaisr7K 15304393 (Pubitemid 39620172)
10. X Wan N Shen A Mendoza C Khanna LJ Helman 2006 CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling Neoplasia 8 394 401 10.1593/neo.05820 10.1593/neo.05820 1:CAS:528:DC%2BD28XovVKks7o%3D 16790088 (Pubitemid 43830746)
11. MS Neshat IK Mellinghoff C Tran, et al. 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 10314 10319 10.1073/pnas.171076798 10.1073/pnas.171076798 1:CAS:528: DC%2BD3MXmvFWiurk%3D 11504908 (Pubitemid 32803017)
12. Y Shi J Gera L Hu, et al. 2002 Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 5027 5034 1:CAS:528:DC%2BD38Xmslyksrk%3D 12208757
13. B Geoerger K Kerr CB Tang, et al. 2001 Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/ medulloblastoma models as single agent and in combination chemotherapy Cancer Res 61 1527 1532 1:CAS:528:DC%2BD3MXhvVeltb8%3D 11245461
14. K Podsypanina RT Lee C Politis, et al. 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci USA 98 10320 10325 10.1073/pnas.171060098 10.1073/pnas.171060098 1:CAS:528:DC%2BD3MXmvFWiurY%3D 11504907 (Pubitemid 32803018)
15. MB Atkins M Hidalgo WM Stadler, et al. 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918 10.1200/JCO.2004.08.185 10.1200/JCO.2004.08.185 1:CAS:528:DC%2BD2cXpsVKisr0%3D 14990647 (Pubitemid 41103603)
16. G Hudes M Carducci P Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086 (Pubitemid 46849157)
17. SM Ansell DJ Inwards KM Rowland Jr, et al. 2008 Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group Cancer 113 508 514 10.1002/cncr.23580 10.1002/cncr.23580 1:CAS:528:DC%2BD1cXpvVWns7Y%3D 18543327
18. TE Witzig SM Geyer I Ghobrial, et al. 2005 Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 5347 5356 10.1200/JCO.2005.13.466 10.1200/JCO.2005.13.466 1:CAS:528: DC%2BD2MXpslOrtLk%3D 15983389 (Pubitemid 46206988)
19. Hess G, Romaguera J, Verhoef G, et al (2008) Phase 3 study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J Clin Oncol 26: Abstract 8513
20. Smith SM, Pro B, Cisneros A, et al (2008) Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol 26: Abstract 8514
21. Oza AM, Elit L, Provencher D, et al (2008) A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 26:26. Abstract 5516. doi: 10.1200/JCO.2007.15.8808
22. E Raymond J Alexandre S Faivre, et al. 2004 Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2336 2247 10.1200/JCO.2004.08.116 10.1200/JCO.2004.08.116 1:CAS:528:DC%2BD2cXpsVWltbc%3D 15136596 (Pubitemid 41115390)
23. S Chan ME Scheulen S Johnston, et al. 2005 Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 5314 5322 10.1200/JCO.2005.66.130 10.1200/JCO.2005.66.130 1:CAS:528:DC%2BD2MXpslOrtLo%3D 15955899 (Pubitemid 46206985)
24. Farag SS, Zhang S, Miller M, et al (2006) Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results. J Clin Oncol 24: Abstract 7616
25. M Hidalgo JC Buckner C Erlichman, et al. 2006 A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer Clin Cancer Res 12 5755 5763 10.1158/1078-0432.CCR-06-0118 10.1158/1078-0432.CCR-06-0118 1:CAS:528:DC%2BD28XhtVartbvK 17020981 (Pubitemid 44629606)
26. Jusko WJ (1992) Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Thrapeutics, Inc., Vancouver, WA, pp 1-43
27. Rapamune® (sirolimus) oral solution and tablets [package insert] (2007) Wyeth Pharmaceuticals Inc, Philadelphia, PA
28. Baselga J, Fumoleau P, Gil M, et al (2004) Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. J Clin Oncol 22:22. Abstract 544. doi: 10.1200/JCO.2004.12.903 (Pubitemid 41103583)
29. J Baselga H Roche P Fumoleau, et al. 2005 Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study Breast Cancer Res Treat 100 S286
30. LWC Chow Y Sun J Jassem, et al. 2006 Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer Breast Cancer Res Treat 100 S286
31. Torisel® (temsirolimus) [package insert] (2007) Wyeth Pharmaceuticals Inc, Philadelphia, PA
32. European Public Assessment Report on Torisel February 04, 2008. http://www.emea.europa.eu/humandocs/Humans/EPAR/torisel/torisel.htm. Accessed 22 Sep 2008
33. SM Chang J Kuhn P Wen, et al. 2004 Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Invest New Drugs 22 427 435 10.1023/B:DRUG.0000036685.72140. 03 10.1023/B:DRUG.0000036685.72140.03 1:CAS:528:DC%2BD2cXmt1ajsL8%3D 15292713 (Pubitemid 39619819)
34. E Galanis JC Buckner MJ Maurer, et al. 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 5294 5304 10.1200/JCO.2005.23.622 10.1200/JCO.2005.23.622 1:CAS:528:DC%2BD2MXpslOrtLw%3D 15998902 (Pubitemid 46206983)